50 minutes ago
At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.
1 hour ago
UNOS data on 82,014 candidates show ALD accounted for 39.0% of steatotic liver disease transplant listings from 2014 to 2024.
1 hour ago
UNOS data on 82,014 candidates show ALD accounted for 39.0% of steatotic liver disease transplant listings from 2014 to 2024.
4 hours ago
Peter Libby, MD, discusses the neutral ZEUS trial and how coronary inflammation imaging could guide anti-inflammatory therapy in atherosclerosis.
4 hours ago
Timothy Craig, DO, outlines stepwise CSU care, from antihistamine updosing to omalizumab, dupilumab, and the oral BTK inhibitor remibrutinib.